Efrati

Revision as of 23:57, 10 October 2018 by Gordoben (talk | contribs) (Imported from Wikispaces)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

There is some weak evidence to support the benefit of hyperbaric oxygen in patients more than six months after stroke

Clinical bottom line:
**1. There is some limited evidence that HBO improves disability more than six months after stroke
    • Citation: Efrati S, Fishlev G, Bechor Y et al. Hyperbaric oxygen induces late neuroplasticity in post stroke patients-Randomized prospective trial. PLoS ONE 2013;8 (1): e53716.doi:10.1371/journal.pone.0053716
    • Lead author's name and email: Shai Efrati: efratishai@013.net
    • T'hree-part Clinical Question: Does hyperbaric oxygen improve disability in post stroke patients?
    • Search Terms: stroke, neuroplasticity
    • The Study:Single-blinded randomised controlled trial without intention-to-treat.The Study Patients: Adult patients at least six months after stroke and at least one motor deficit. Control group (N = 37; 29 analysed): Usual physiotherapy for 8 weeks, then cross over to hyperbaric oxygen.Experimental group (N = 37; 30 analysed): Standard care plus 40 sessions of HBO at 2ATA for 90 minutes daily for 8 weeks.
    • The Evidence:
Measure Control Group HBO Group Difference 95% CI
^ Mean SD Mean SD ^ ^
National Institutes of Health Stroke Scale (0normal, 42most severe deficit)
at 8 weeks
8.3 4.3 5.5 3.6 2.8 0.77 to 4.87
Activity of Daily Living (scale unknown) 17.6 9.5 12.8 7.3 4.7 0.27 to 9.09
Quality of Life (EQ-5D) (scale unknown) 8.6 1.7 7.7 1.3 1.0 0.18 to 1.76
Quality of Life (EQ-VAS) (sclae unknown) 5.3 2.3 6.5 1.5 1.3 0.2 to 2.2
    • Comments:

1. The unblinded study design may have contributed to positive bias from patient and staff perception. Chamber confinement is accepted as a powerful placebo. 2.There was no neurologist involved in the trial which seems unusual. 3. Assessment of the clinical benefit of a mean improvement of 2.8 in NIHSS score requires specialist interpretation, but seems unlikely to be a signficant gain. 4. The outcomes are very short term and may not persist. 5. There is patient data missing from each graph in Figure 2. 6. The EQ-VAS mean improvement of 4.9 to 6.5 is extremely small on a scale of 1-100. Probably mis-reported and is actually a scale from 1 to 10.

    • Appraised by:

Alan Bourke and Michael bennett; Sunday, 11th April 2013 Email: alan.bourke@sesiahs.health.nsw.gov.au

    • Kill or Update By: July 2022

File:Http://www.hboevidence.com/ themes/copy-of-sumi-painting/sumhorsa.gif

Sumhorsa.gif

BACK